Quidel to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on February 12, 2013
January 31 2013 - 6:30PM
Marketwired
Quidel Corporation (NASDAQ: QDEL), a leading
provider of rapid diagnostic testing solutions and cellular-based
virology assays, will release fourth quarter and full year 2012
financial results after market close on Tuesday, February 12, 2013.
Following the release of results, Douglas Bryant, president and
chief executive officer, and Randy Steward, chief financial
officer, will host an investment community conference call
beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to
discuss the results and answer questions. During the conference
call, the company will also discuss business and financial
developments and trends. The company's statements may contain or
constitute material information that has not been previously
disclosed.
To participate in the live call by telephone from the U.S., dial
866-730-5769, or from outside the U.S. dial 857-350-1593, and enter
the pass code 75220493.
A live webcast of the call can be accessed at
http://www.quidel.com, and the Web site replay will be available
for 14 days. The telephone replay will be available for 48 hours
beginning at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time) on
February 12 by dialing 888-286-8010 from the U.S., or 617-801-6888
for international callers, and entering pass code 87777394.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
QuickVue®, D3® Direct Detection and Thyretain® leading brand names,
as well as under the new Sofia® and AmpliVue® brands, Quidel's
products aid in the detection and diagnosis of many critical
diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid
disease and fecal occult blood. Quidel's research and development
engine is also developing a continuum of diagnostic solutions from
advanced lateral-flow and direct fluorescent antibody to molecular
diagnostic tests to further improve the quality of healthcare in
physicians' offices and hospital and reference laboratories. For
more information about Quidel's comprehensive product portfolio,
visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931 Media and Investors Contact: Quidel
Corporation Ruben Argueta (858) 646-8023 Email Contact
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024